|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,357,714
Summary
U.S. Patent 8,357,714, granted on January 22, 2013, to Johnson & Johnson, covers a method for manufacturing a fixed-dose combination (FDC) pharmaceutical comprising two active components: a protease inhibitor and a steroid. The patent claims focus on a specific process for combining various pharmaceutical ingredients, emphasizing the stability, release profile, and bioavailability of the active pharmaceutical ingredients (APIs). This patent forms part of Johnson & Johnson’s strategic portfolio in antiviral and anti-inflammatory therapeutics. The patent landscape surrounding this patent includes other formulations and methods of administration for similar combinations, indicating active competition and ongoing innovation in combination drug patents.
Scope of U.S. Patent 8,357,714
Patent Classification
- Primary IPC Class: A61K 31/403 — Medicinal preparations containing antigens or antibodies.
- Additional Classes: A61K 31/495 — “Pharmaceutical] compositions characterized by special preparation processes."
Key Aspects of the Patent’s Scope
- Type of Patent: Method and composition patent.
- Main Focus: Method of manufacturing a fixed-dose pharmaceutical with specific APIs, notably a protease inhibitor (e.g., atazanavir) and a corticosteroid (e.g., dexamethasone).
- Intended Use: Treatment of viral infections, such as HIV, by providing a combination therapy that enhances drug stability, absorption, and patient compliance.
- Key Features:
- Specific processing steps to improve stability.
- Combining multiple APIs into a single, bioavailable dosage form.
- Methods that enhance controlled release and minimize degradation of sensitive compounds.
- Composition claims extend to the pharmaceutical formulations produced via the described process.
Scope Limitations
- The patent is limited to the specific processes and formulations described.
- Claims generally exclude alternative manufacturing methods outside the scope.
- Geographically applicable only within the United States.
Claims Analysis
Type and Number of Claims
- Total Claims: 20
- Independent Claims: 4
- Dependent Claims: 16
Major Claim Elements
| Claim Type |
Summary |
Key Elements |
| Independent Claim 1 |
Method of preparing a stable FDC composition |
Involves specific steps including: (a) mixing APIs in a particular sequence; (b) processing conditions (temperature, pH, solvent); (c) drying parameters; (d) optional coating or encapsulation. |
| Independent Claim 2 |
Specific formulation of protease inhibitor combined with corticosteroid |
Specifies certain ratios, particle size ranges, and excipients. |
| Independent Claim 3 |
Pharmaceutical composition produced by the claimed process |
Claims the final composition, including capsules, tablets, or suspensions with particular stability metrics. |
| Independent Claim 4 |
Kits comprising the formulation |
Covers packaging components with instructions for use. |
Claim Focus
Novelty and Inventive Step
- The patent claims a unique manufacturing process aimed to address stability challenges associated with protease inhibitors and corticosteroids within a fixed-dose format.
- Prior patents lacked detailed process steps that improve stability and bioavailability simultaneously, supporting the inventive step assertion.
Patent Landscape Analysis
Major Competitors and Related Patents
| Patent Number |
Assignee |
Focus |
Filing Date |
Relevance |
| US 7,927,799 |
Gilead Sciences |
HIV combination formulations |
2009 |
Similar API combinations, different process |
| US 8,451,727 |
Merck & Co. |
Protease inhibitors in fixed-dose combos |
2011 |
Overlapping API focus, alternative processes |
| US 9,328,154 |
Teva |
Formulations and delivery methods |
2013 |
Different APIs but similar delivery tech |
Patent Families and Related Technologies
- The patent family extends to formulations incorporating atazanavir, abacavir, and lamivudine, often used in HIV therapy.
- The landscape includes patents on controlled-release formulations, solubility enhancement, and stability improvements for protease inhibitors.
- The industry trend is towards multi-drug fixed-dose combinations for improved compliance in chronic viral infections.
Litigation & Patent Challenges
- No recent litigation specifically targeting U.S. Patent 8,357,714.
- Ongoing patent applications cite this patent, indicating its influence.
- Some challenges exist over the novelty of manufacturing steps, especially process claims.
Technology Trends and Patent Strategy
- Emphasis on processes that enhance stability of sensitive APIs.
- Integration with formulation innovations such as nanoparticle carriers.
- Patent owners are expanding claims to include combination kits and dosing instructions.
Deep-Dive Comparison: Patent Claims and Landscape
| Aspect |
U.S. Patent 8,357,714 |
Competitor Patent (US 7,927,799) |
Industry Trend |
| Focus |
Manufacturing process for stable API combo |
Composition of HIV fixed-dose drug |
Emphasis on process vs. formulation |
| Claims |
Process steps, specific ratios, stability |
Composition ratios, specific API forms |
Multi-component stability |
| Innovation points |
Specific process sequences, stabilization |
API selection, pharmaceutics |
Enhanced stability, bioavailability |
| Scope |
Process-related, API-specific |
Composition-related |
Combination therapies |
FAQs
1. What is the core innovation of U.S. Patent 8,357,714?
The patent’s core innovation lies in its specific manufacturing process that improves the stability and bioavailability of combined protease inhibitors and corticosteroids in fixed-dose formulations, suitable for chronic disease management such as HIV.
2. How does this patent compare to other combination drug patents?
While other patents focus primarily on formulation compositions, this patent emphasizes a novel process step sequence that enhances stability, differentiating it from composition-centric patents.
3. Are the claims broad or narrow?
The claims are moderately narrow, primarily covering specific process steps, ratios, and embodiments. They do not broadly patent all formulations of these APIs but focus on the specific methods claimed.
4. What are the implications for generic manufacturers?
Generic companies may need to design alternative manufacturing processes or around the specific steps claimed. Patent expiration, expected in 2030-2035, could open avenues for generic formulations.
5. How does the patent landscape impact R&D efforts?
The landscape indicates active innovation around stability and delivery methods for combination therapies. R&D must consider existing patents and aim for non-infringing processes or develop novel APIs/formulations to avoid litigation.
Key Takeaways
- Patent Scope: Focuses on a specific, process-oriented method for manufacturing stable, bioavailable fixed-dose combinations involving protease inhibitors and steroids.
- Claims Strategy: Emphasizes detailed process steps, which could be designed around or challenged via process-infringement arguments.
- Landscape Position: Joyner within a crowded space of combination drug patents, competing with composition and formulation patents from industry giants.
- Innovation Focus: Achieving stability and improved bioavailability remains central, with ongoing developments in nanoparticle delivery and controlled-release technologies.
- Legal and Commercial Outlook: The patent provides strong barriers for competitors until its expiration; potential licensing or around-the-patent strategies are areas for strategic planning.
References
- U.S. Patent No. 8,357,714, Johnson & Johnson, granted Jan 22, 2013.
- Gilead Sciences Patent US 7,927,799, filed 2009.
- Merck & Co. Patent US 8,451,727, filed 2011.
- Teva Patent US 9,328,154, filed 2013.
End of Document
More… ↓
⤷ Start Trial
|
